Key Takeaways
- Shares of BIAF climbed more than 55% Tuesday following news that CyPath Lung may be used to monitor lung cancer survivors for recurrence
- BioAffinity Technologies is investigating whether CyPath Lung can detect cancer returning in patients who completed treatment with curative intent
- More than 680,000 Americans were living with a history of lung cancer as of the start of 2025
- Share volume surpassed 17 million, significantly higher than the three-month average of 5.91 million
- Spark’s AI analyst assigns BIAF an Underperform rating with a $5.50 target, pointing to cash depletion and falling revenue
Shares of BioAffinity Technologies rallied over 55% Tuesday after the medical diagnostics firm disclosed it is developing CyPath Lung for monitoring lung cancer survivors.
bioAffinity Technologies, Inc., BIAF
Trading began with shares already elevated, having gained 65.57% during premarket hours. This came after a 6.37% decline in the prior session. Despite Tuesday’s rally, BIAF remains down 74.24% year-to-date and has fallen 95.72% over the trailing twelve months.
BioAffinity revealed it is investigating whether CyPath Lung can serve as a surveillance mechanism for cancer recurrence in individuals who have completed treatment intended to cure their disease.
Data from the American Cancer Society indicates that over 680,000 people in the United States were living with a previous lung cancer diagnosis at the beginning of 2025. The National Cancer Institute projects approximately 230,000 new diagnoses in 2026.
When patients complete therapy, discovering a new pulmonary nodule during imaging can generate significant diagnostic uncertainty. While CT scans can identify nodules, they often cannot definitively determine whether the finding represents cancer recurrence, a fresh malignancy, or benign treatment-related changes like scar tissue or inflammation.
The CyPath Lung test delivers a straightforward result: either “unlikely” or “likely” malignancy. This classification could assist physicians in determining which patients require additional workup versus those suitable for continued routine surveillance.
Research literature indicates that non-small cell lung cancer recurs in 20% to 55% of cases, with variation based on disease stage and therapy approach. Clinical guidelines from the American Society of Clinical Oncology call for surveillance scans every six months for two years following curative-intent therapy for stage I through III NSCLC.
Performance Data for CyPath Lung
CyPath Lung employs flow cytometry combined with proprietary artificial intelligence to evaluate cellular populations in patient sputum samples. Published trial results demonstrated 92% sensitivity, 87% specificity, 88% overall accuracy, and a 99% negative predictive value when detecting early-stage lung cancer in high-risk individuals.
According to BioAffinity, three years of real-world commercial deployment have demonstrated the test’s ability to help clinicians evaluate malignancy probability and inform patient management, including situations where imaging findings and risk prediction models yield contradictory information.
Company CEO Maria Zannes stated the firm believes post-treatment surveillance “has the potential to lead to earlier intervention” and could complement existing early detection approaches.
Texas Oncology’s Dr. Vijay Gunuganti noted that CyPath Lung “can provide additional information without immediately subjecting the patient to an invasive procedure.”
Chief Medical Officer Dr. Gordon Downie emphasized that completing treatment represents “not the end of cancer care,” highlighting the expanding role of survivorship surveillance programs.
Trading Activity and Wall Street Perspective
Share volume Tuesday exceeded 17 million, well above the three-month daily average of approximately 5.91 million. Such dramatic volume increases typically indicate strong retail investor interest responding to breaking news.
CyPath Lung operates as a Laboratory Developed Test and lacks regulatory clearance as an independent diagnostic device. The clinical performance metrics referenced pertain to the detection application and have not undergone separate validation for post-treatment monitoring scenarios.
Spark’s AI analyst maintains an Underperform rating on BIAF with a $5.50 price target, highlighting severe cash consumption, declining revenue trends, and potential Nasdaq delisting as primary concerns.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
